3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm Metastasis
1
Leukemia
1
Genital Neoplasms, Female
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Interventions
Cytarabine
5
Whole-Body Irradiation
4
fludarabine
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Injections
3
Cyclophosphamide
3
CPX-351
3
Blood Specimen Collection
3
venetoclax
2
nilotinib
2
luspatercept
2
ivosidenib
2
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
asciminib
2
Tacrolimus
2
Mycophenolic Acid
2
Melphalan
2
Liposomes
2
Idarubicin
2
Granulocyte Colony-Stimulating Factor
2
Gemtuzumab
2
Filgrastim
2
Daunorubicin
2
Cyclosporine
2
Busulfan
2
Biopsy
2
Azacitidine
2
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
nilotinib
×
30 days
×
Clear all
NCT04877522
2026-06-10
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled
NCT05456191
2026-05-27
ASC4START
Novartis
Phase 3
Active not recruiting
568 enrolled
11 charts